OFF-LABEL USE DATA IN "INTERMEDIATE" DRUG LABELING OFFERS POTENTIAL COMPROMISE BETWEEN INDUSTRY, CLINICIANS AND FDA, ATTORNEY COOPER SUGGESTS AT FDLI
Co-development by pharmaceutical companies and FDA of hybrid labeling for off-label uses may be one way to satisfy the objectives of industry, clinicians and FDA regarding unapproved uses of drugs, Williams & Connelly partner Richard Cooper proposed May 24 at the Food & Drug Law Institute's Pharmaceutical Update '94 in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth